- Home
- ALLO vs CATX Comparison
ALLO vs CATX Comparison
Compare ALLO & CATX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALLO
- CATX
- Stock Information
- Founded
- ALLO 2017
- CATX 1983
- Country
- ALLO United States
- CATX United States
- Employees
- ALLO N/A
- CATX N/A
- Industry
- ALLO Biotechnology: Biological Products (No Diagnostic Substances)
- CATX Medical/Dental Instruments
- Sector
- ALLO Health Care
- CATX Health Care
- Exchange
- ALLO Nasdaq
- CATX Nasdaq
- Market Cap
- ALLO 252.9M
- CATX 239.0M
- IPO Year
- ALLO 2018
- CATX N/A
- Fundamental
- Price
- ALLO $1.44
- CATX $3.71
- Analyst Decision
- ALLO Buy
- CATX Strong Buy
- Analyst Count
- ALLO 12
- CATX 10
- Target Price
- ALLO $8.80
- CATX $12.90
- AVG Volume (30 Days)
- ALLO 2.9M
- CATX 807.4K
- Earning Date
- ALLO 11-06-2025
- CATX 11-11-2025
- Dividend Yield
- ALLO N/A
- CATX N/A
- EPS Growth
- ALLO N/A
- CATX N/A
- EPS
- ALLO N/A
- CATX N/A
- Revenue
- ALLO N/A
- CATX $1,235,000.00
- Revenue This Year
- ALLO N/A
- CATX N/A
- Revenue Next Year
- ALLO $100.00
- CATX N/A
- P/E Ratio
- ALLO N/A
- CATX N/A
- Revenue Growth
- ALLO N/A
- CATX N/A
- 52 Week Low
- ALLO $0.86
- CATX $1.60
- 52 Week High
- ALLO $3.78
- CATX $13.44
- Technical
- Relative Strength Index (RSI)
- ALLO 64.79
- CATX 53.74
- Support Level
- ALLO $1.29
- CATX $3.37
- Resistance Level
- ALLO $1.43
- CATX $3.78
- Average True Range (ATR)
- ALLO 0.07
- CATX 0.20
- MACD
- ALLO 0.02
- CATX 0.04
- Stochastic Oscillator
- ALLO 78.17
- CATX 66.14
About ALLO Allogene Therapeutics Inc.
Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.
About CATX Perspective Therapeutics Inc.
Perspective Therapeutics Inc is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha-emitting isotope Lead-212 (212Pb) to deliver powerful radiation specifically to cancer cells via specialized targeting moieties.